b-blockers in sympathetic regulation of vascular tonus and endothelial function

Links

• 1. Воронков Л.Г. (2003) Бета-адреноблокаторы при хронической сердечной недостаточности: итоги и перспективы. Укр. кардіол. журн., 3: 14–19.
• 2. Дыкун Я.В. (2002) Современные бета-адреноблокаторы в кардиологии. Словакофарма-ревю: 28–32.
• 3. Лишневская В.Ю. (2007) Бета-адреноблокаторы в лечении заболеваний сердечно-сосудистой системы. Therapia. Український медичний вісник, 5: 36–38.
• 4. Марцевич С.Ю. (2002) Бета-адреноблокаторы: современные подходы к применению. Тер. арх., 1: 67–70.
• 5. Целуйко В.И., Ляшенко А.Я. (2002) Эффективность бетаксолола при лечении метаболического синдрома Х. Укр. кардіол. журн., 5: 24–27.
• 6. Ahmad S., Chretien P., Daniel E.E., Shen S.H. (1990) Characterization of beta adrenoceptors on cultured endothelial cells by radioligand binding. Life Sci., 47 (25): 2365–2370.
• 7. Brehm B.R., Bertsch D., von Fallois J., Wolf S.C. (2000) Beta-blockers of the third generation inhibit endothelin-1 liberation, mRNA production and proliferation of human coronary smooth muscle and endothelial cells. J. Cardiovasc. Pharmacol., 36(5 Suppl. 1): S401–S403.
• 8. Brehm B.R., Wolf S.C., Bertsch D. et al. (2001) Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc. Res., 49(2): 430–439.
• 9. Chin B.S., Gibbs C.R., Blann A.D., Lip G.Y. (2003) Neither carvedilol nor bisoprolol in maximally tolerated doses has any specific advantage in lowering chronic heart failure oxidant stress: implications for beta-blocker selection. Clin. Sci. (Lond), 105(4): 507–512.
• 10. Cockcroft J.R., Chowienczyk P.J., Brett S.E. et al. (1995) Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J. Pharmacol. Exp. Ther., 274(3): 1067–1071.
• 11. Cosentino F., Bonetti S., Rehorik R. et al. (2002) Nitric-oxide-mediated relaxations in salt-induced hypertension: effect of chronic beta1-selective receptor blockade. J. Hypertens., 20(3): 421–428.
• 12. Cruickshank J. M. (2000) Beta-blockers continue to surprise us. Eur. Heart J., 21(5): 354–364.
• 13. Cruickshank J.M., Prichard B.N.C. (1994) Beta-blockers in Clinical Practice. 2nd edn., Churchill Livingstone, Edinburgh, London, Madrid, Melbourne, New York, Tokyo, 988 p.
• 14. Franciosa J.A. (1999) Beta-adrenergic blocking agents: past, present, and future perspectives. Coron. Artery Dis., 10 (6): 369–376.
• 15. Franciosa J.A., Massie B.M., Lukas M.A. et al. (2004) Beta-Blocker therapy for heart failure outside the clinical trial setting: findings of a community-based registry. Am. Heart J., 148 (4): 718–726.
• 16. Graf K., Dummler U, Grafe M. et al. (1995) Effect of theophylline on beta-adrenergic receptor density and cAMP content in bovine aortic smooth muscle cells. Inflamm. Res., 44 (8): 323–326.
• 17. Graf K., Grafe M, Dummler U. et al. (1993) Regulation of beta-adrenergic receptors on endothelial cells in culture. Eur. Heart J., 14 (Suppl. I): 173–176.
• 18. Horani M.H., Haas M.J., Mooradian A.D. (2006) Suppression of hyperglycemia-induced superoxide formation and endothelin-1 gene expression by carvedilol. Am. J. Ther., 13(1): 2–7.
• 19. Howell R.E., Albelda S.M., Daise M.L., Levine E.M. (1988) Characterization of beta-adrenergic receptors in cultured human and bovine endothelial cells. J. Appl. Physiol., 65 (3): 1251–1257.
• 20. Johnson M. (2001) Beta2-adrenoceptors: mechanism of action of beta2-agonists. Paediatr. Respir. Rev., 2(1): 57–62.
• 21. Krum H., Gu A., Wiltshire-Clement M. et al. (1996) Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure. Am. Heart J., 131(2): 337–341.
• 22. Maggioni A. (2005) Review of the new ESC guidelines for the pharmacological management of chronic heart failure. Eur. Heart J., 7: J15–J20.
• 23. Massart P.E., Donckier J., Kyselovic J. et al. (1999) Carvedilol and lacidipine prevent cardiac hypertrophy and endothelin-1 gene overexpression after aortic banding. Hypertension, 34(6): 1197–1201.
• 24. Matheson M.C., Ellis J.A., Raven J. et al. (2006) Beta₂-adrenergic receptor polymorphisms are associated with asthma and COPD in adults. J. Hum. Genet., 51(11): 943–951.
• 25. Nakajima T., Ma J., Iida H. et al. (2003) Inhibitory effects of carvedilol on calcium channels in vascular smooth muscle cells. Jpn. Heart J., 44(6): 963–978.
• 26. Ohlstein E.H., Vickery L., Arleth A. et al. (1994) Carvedilol, a novel cardiovascular agent, inhibits development of vascular and ventricular hypertrophy in spontaneously hypertensive rats. Clin. Exp. Hypertens., 16(2): 163–177.
• 27. Puddu P., Puddu G.M., Cravero E., Muscari A. (2004) Different effects of antihypertensive drugs on endothelial dysfunction. Acta Cardiol., 59(5): 555–564.
• 28. Rozec B., Quang T.T., Noireaud J., Gauthier C. (2006) Mixed beta₃-adrenoceptor agonist and alpha1-adrenoceptor antagonist properties of nebivolol in rat thoracic aorta. Br. J. Pharmacol., 147(7): 699–706.
• 29. Saenz de Tejada I., Moncada J., Orte L. et al. (1996) b-blockers potentіate the constrictor response of human helicine arteries to catecholamines. Int. J. Imp. Res., 8: D25.
• 30. Sendon J.L., Swedberg K., McMuray J. et al. (2005) Консенсус щодо застосування блокаторів бета-адренергічних рецепторів. Укр. кардіол. журн., Додаток 1: 4–20.
• 31. Taddei S., Virdis A., Ghiadoni L. et al. (2002) Effects of antihypertensive drugs on endothelial dysfunction: clinical implications. Drugs, 62(2): 265–284.
• 32. Turnes J., Hernandez-Guerra M., Abraldes J.G. et al. (2006) Influence of beta₂-adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis. Hepatology, 43(1): 34–41.
• 33. Xiang Y., Naro F., Zoudilova M. et al. (2005) Phosphodiesterase 4D is required for beta₂-adrenoceptor subtype-specific signaling in cardiac myocytes. Proc. Natl. Acad. Sci. USA., 102(3): 909–914.
• 34. Yonemochi H., Saikawa T., Yasunaga S. et al. (1997) Angiotensin-converting enzyme inhibitor up-regulates cardiac beta-receptors in cultured neonatal rat myocytes. Jpn. Circ. J., 61(2): 170–179.